Travere Therapeutics, Inc. (TVTX)

Market Cap	4.13B +127.6%
Revenue (ttm)	536.20M +96.0%
Net Income	-21.42M
EPS	-0.24
Shares Out	92.99M
PE Ratio	n/a
Forward PE	17.22
Dividend	n/a
Ex-Dividend Date	n/a

Volume	803,359
Open	44.39
Previous Close	44.74
Day's Range	44.12 - 45.00
52-Week Range	13.88 - 48.61
Beta	1.14
Analysts	Strong Buy
Price Target	53.57 (+20.57%)
Earnings Date	May 4, 2026

About TVTX

Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases in the United States. The company’s products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urin...

• Industry: Biotechnology
• Sector: Healthcare
• CEO: Eric Dube
• Employees: 497
• Stock Exchange: NASDAQ
• Ticker Symbol: TVTX
• Website: https://travere.com

Financial Performance

In 2025, Travere Therapeutics's revenue was $490.73 million, an increase of 110.45% compared to the previous year's $233.18 million. Losses were -$25.55 million, -92.06% less than in 2024.

Analyst Summary

According to 15 analysts, the average rating for TVTX stock is "Strong Buy." The 12-month stock price target is $53.57, which is an increase of 20.57% from the latest price.

Price Target

$53.57

(20.57% upside)

Analyst Consensus: Strong Buy